MétaCan
Menu
Back to cohort
Record W4388501064 · doi:10.1097/cce.0000000000000997

Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis

2023· article· en· W4388501064 on OpenAlexafffund
Patrick R. Lawler, Garen Manvelian, Alida Coppi, Amy Damask, Michael Cantor, Manuel A. R. Ferreira, Charles Paulding, Nilanjana Banerjee, Dadong Li, Richa Attre, David J. Carey, Kristi Krebs, Lili Milani, Kristian Hveem, Jan Kristian Damås, Erik Solligård, Stefan Stender, Anne Tybjærg‐Hansen, Børge G. Nordestgaard, Tamara Hernández-Beeftink, Tormod Rogne, Carlos Flores, Jesús Villar, Keith R. Walley, Vincent X. Liu, Alison E. Fohner, Luca A. Lotta, Christos A. Kyratsous, Mark W. Sleeman, Michel Scemama, Richard DelGizzi, Robert Pordy, Julie Horowitz, Aris Baras, Greg S. Martin, Philippe Gabríel Steg, Gregory G. Schwartz, Michael Szarek, Shaun G. Goodman

Bibliographic record

VenueCritical Care Explorations · 2023
Typearticle
Languageen
FieldMedicine
TopicSepsis Diagnosis and Treatment
Canadian institutionsCanadian VIGOUR CentreUniversity of AlbertaSt. Michael's HospitalMcGill University Health CentreUniversity Health NetworkUniversity of TorontoUniversity of British Columbia
FundersDuke Clinical Research InstituteNorwegian Institute of Public HealthFaculty of Medicine and Health, University of SydneyEuropean Regional Development FundAmerican RegentEsperion TherapeuticsSilence TherapeuticsHLS TherapeuticsIdorsia PharmaceuticalsServierNovo NordiskMyoKardiaDaiichi-SankyoMedicines CompanyTartu ÜlikoolAstraZenecaAmarin CorporationLifeArcNational Institutes of HealthRegeneron PharmaceuticalsSanofiNorges Teknisk-Naturvitenskapelige UniversitetPfizerYork UniversityCleveland ClinicBristol-Myers SquibbKaiser PermanenteEli Lilly and CompanyCSL BehringUniversity of TorontoEesti TeadusagentuurBrigham and Women's HospitalHeart and Stroke Foundation of CanadaEuropean CommissionKowa CompanyInstituto de Salud Carlos IIIHelse Midt-NorgeAmgen
KeywordsKexinProprotein convertaseSubtilisinDownregulation and upregulationSepsisPCSK9MedicineBiologyInternal medicineGeneGeneticsEnzymeBiochemistryCholesterolLDL receptorLipoprotein

Abstract

fetched live from OpenAlex

OBJECTIVES: Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies—lipoproteins play critical roles in clearing pathogens from the bloodstream. We investigated whether early inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) may accelerate bloodstream clearance of immunogenic bacterial lipids and improve sepsis outcomes. DESIGN: Genetic and clinical epidemiology, and experimental models. SETTING: Human genetics cohorts, secondary analysis of a phase 3 randomized clinical trial enrolling patients with cardiovascular disease (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402), and experimental murine models of sepsis. PATIENTS OR SUBJECTS: Nine human cohorts with sepsis (total n = 12,514) were assessed for an association between sepsis mortality and PCSK9 loss-of-function (LOF) variants. Incident or fatal sepsis rates were evaluated among 18,884 participants in a post hoc analysis of ODYSSEY OUTCOMES. C57BI/6J mice were used in Pseudomonas aeruginosa and Staphylococcus aureus bacteremia sepsis models, and in lipopolysaccharide-induced animal models. INTERVENTIONS: Observational human cohort studies used genetic PCSK9 LOF variants as instrumental variables. ODYSSEY OUTCOMES participants were randomized to alirocumab or placebo. Mice were administered alirocumab, a PCSK9 inhibitor, at 5 mg/kg or 25 mg/kg subcutaneously, or isotype-matched control, 48 hours prior to the induction of bacterial sepsis. Mice did not receive other treatments for sepsis. MEASUREMENTS AND MAIN RESULTS: Across human cohort studies, the effect estimate for 28-day mortality after sepsis diagnosis associated with genetic PCSK9 LOF was odds ratio = 0.86 (95% CI, 0.67–1.10; p = 0.24). A significant association was present in antibiotic-treated patients. In ODYSSEY OUTCOMES, sepsis frequency and mortality were infrequent and did not significantly differ by group, although both were numerically lower with alirocumab vs. placebo (relative risk of death from sepsis for alirocumab vs. placebo, 0.62; 95% CI, 0.32–1.20; p = 0.15). Mice treated with alirocumab had lower endotoxin levels and improved survival. CONCLUSIONS: PCSK9 inhibition may improve clinical outcomes in sepsis in preventive, pretreatment settings.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.273
Threshold uncertainty score0.321

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.168
GPT teacher head0.405
Teacher spread0.238 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes2
Has abstractyes

Explore more

Same venueCritical Care ExplorationsSame topicSepsis Diagnosis and TreatmentFrench-language works237,207